Bayer/Merck Cardio Rx Collaboration Pumped Up By Consumer Deal
This article was originally published in The Pink Sheet Daily
Merck sells consumer care business, but also buys into Bayer’s franchise of sGC modulators.
You may also be interested in...
Efficacy seen in reducing hospitalization in high-risk heart failure patients, but not in reducing the risk of cardiovascular death. Analysts say this portends a more niche opportunity for vericiguat.
The Phase III VICTORIA study evaluating the safety of the sGC stimulator met its primary endpoint.
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.